title: Bench-to-bedside review: Paediatric viral lower respiratory tract disease necessitating mechanical ventilation--should we use exogenous surfactant?
abstract: Treatment of infants with viral lower respiratory tract disease (LRTD) necessitating mechanical ventilation is mainly symptomatic. The therapeutic use of surfactant seems rational because significantly lower levels of surfactant phospholipids and proteins, and impaired capacity to reduce surface tension were observed among infants and young children with viral LRTD. This article reviews the role of pulmonary surfactant in the pathogenesis of paediatric viral LRTD. Three randomized trials demonstrated improved oxygenation and reduced duration of mechanical ventilation and paediatric intensive care unit stay in young children with viral LRTD after administration of exogenous surfactant. This suggest that exogenous surfactant is the first beneficial treatment for ventilated infants with viral LRTD. Additionally, in vitro and animal studies demonstrated that surfactant associated proteins SP-A and SP-D bind to respiratory viruses, play a role in eliminating these viruses and induce an inflammatory response. Although these immunomodulating effects are promising, the available data are inconclusive and the findings are unconfirmed in humans. In summary, exogenous surfactant in ventilated infants with viral LRTD could be a useful therapeutic approach. Its beneficial role in improving oxygenation has already been established in clinical trials, whereas the immunomodulating effects are promising but remain to be elucidated.
authors.affiliation: Department of Pediatric Intensive Care, VU University Medical Center, Amsterdam, The Netherlands. m.kneyber@vumc.nl
authors.forename: Martin C J
authors.initials: MC
authors.lastname: Kneyber
authors.forename: Frans B
authors.initials: FB
authors.lastname: Plötz
authors.forename: Jan L L
authors.initials: JL
authors.lastname: Kimpen
mesh_terms: D000818:Animals; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007223:Infant; D008170:Lung Compliance / Q000187:drug effects; D010372:Pediatrics / Q000379:methods*; D037662:Pulmonary Surfactant-Associated Protein A / Q000172:deficiency / Q000276:immunology; D037663:Pulmonary Surfactant-Associated Protein D / Q000172:deficiency / Q000276:immunology; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012121:Respiration, Artificial; D012140:Respiratory Tract Diseases / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D013500:Surface Tension / Q000187:drug effects; D016896:Treatment Outcome; D014777:Virus Diseases / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*
chemical_list: D037662:Pulmonary Surfactant-Associated Protein A; D037663:Pulmonary Surfactant-Associated Protein D; D011663:Pulmonary Surfactants